Hopefully something beneficial, but not with 32 mil shares hitting the otc market being the “floor”. There’s a Q coming. Let’s see if Pantheon and MediSource are value added. That’d help. For the deal Gnbt gave their CEO, it must be what they’re actually worth, not some over the top projection of what Generex can make them.